The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

NCT02372630 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Linagliptin
DRUG: Placebo

Sponsor

University at Buffalo

Collaborators

[object Object]